← FDA DRUG APPROVALS

FDA ANDA · ANDA078796

IRINOTECAN HYDROCHLORIDE

Sponsor: HOSPIRA

APPLICATION
ANDA078796
TYPE
ANDA
ORIGINAL APPROVAL
2008-02-27
LATEST ACTION
2020-06-19
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

IRINOTECAN HYDROCHLORIDEPrescription
IRINOTECAN HYDROCHLORIDE 500MG/25ML (20MG/ML) · INJECTABLE · INJECTION

Approval history

2020-06-19Labeling · Supplement 11 · standardAP
2020-06-19Labeling · Supplement 10 · standardAP
2017-12-27Labeling · Supplement 7 · standardAP
2015-01-02Labeling · Supplement 6 · standardAP
2013-01-24Labeling · Supplement 4 · standardAP
2008-02-27OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →